Inactive Instrument

ENTREMED Stock Nasdaq

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-14	Casi Pharmaceuticals, Inc. Announces Management Changes	CI

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	2.56M 2.25M 2.13M 1.93M 3.63M 246M 3.65M 25.52M 9.86M 126M 9.62M 9.41M 403M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.42M 21.47M 20.31M 18.42M 34.59M 2.34B 34.79M 243M 93.9M 1.2B 91.67M 89.69M 3.84B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.46%	Yield 2024 *	-	Yield 2025	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-14	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-15	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-21	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-21	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

08-14	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
07-01	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

ENTREMED Stock Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news: ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.11%	+1.71%	+63.52%	+117.61%	1,056B
JOHNSON & JOHNSON	+0.27%	+0.92%	+51.33%	+73.35%	655B
ABBVIE INC.	+0.73%	+0.68%	+20.70%	+74.90%	471B
ROCHE HOLDING AG	+0.15%	-2.39%	+38.77%	+41.90%	342B
NOVARTIS AG	+0.69%	+4.40%	+22.75%	+29.52%	277B
ASTRAZENECA PLC	+2.05%	+0.76%	+15.15%	+15.01%	257B
AMGEN INC.	+0.85%	+6.35%	+53.17%	+54.39%	226B
GILEAD SCIENCES, INC.	+0.85%	+1.10%	+35.78%	+101.82%	189B
NOVO NORDISK A/S	+0.23%	-2.05%	-27.88%	-60.63%	170B
Average	+0.56%	+0.97%	+30.37%	+49.76%	404.77B
Weighted average by Cap.	+0.25%	+1.04%	+40.62%	+70.03%

	2024	2025
Net sales	28.54M 25.1M 23.73M 21.53M 40.43M 2.74B 40.66M 284M 110M 1.4B 107M 105M 4.49B	20.71M 18.22M 17.23M 15.62M 29.34M 1.99B 29.51M 206M 79.65M 1.01B 77.76M 76.08M 3.26B
Net income	-39.26M -34.53M -32.65M -29.61M -55.62M -3.77B -55.94M -391M -151M -1.92B -147M -144M -6.18B	-48.06M -42.27M -39.97M -36.25M -68.08M -4.61B -68.48M -479M -185M -2.35B -180M -177M -7.56B
Net Debt	6.05M 5.32M 5.03M 4.56M 8.57M 581M 8.62M 60.24M 23.27M 296M 22.71M 22.22M 952M	21.85M 19.22M 18.18M 16.49M 30.96M 2.1B 31.14M 218M 84.05M 1.07B 82.05M 80.27M 3.44B